Advertisement

Index by author

October 01, 1995; Volume 275,Issue 1

A

  1. Aasmundstad, T A

    1. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling.
      T A Aasmundstad, J Mørland and R E Paulsen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 435-441;

  2. Aizawa, T

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  3. Allcock, G H

    1. Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat.
      G H Allcock, B Battistini, A Fournier, T D Warner and J R Vane
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 120-126;

  4. Anglin, C P

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  5. Ator, N A

    1. Drug discrimination analysis of midazolam under a three-lever procedure. II: Differential effects of benzodiazepine receptor agonists.
      C A Sannerud and N A Ator
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 183-193;

  6. Aviv, A

    1. The endothelin receptor profile in L6 myotubes.
      Z Fekete, X Y Yang, M Kimura and A Aviv
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 215-218;

  7. Azuma, Y

    1. TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats.
      T Ohta, Y Azuma, H Kanatani, M Kiyoki and Y Koshihara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 450-455;

B

  1. Babovic-Vuksanovic, D

    1. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
      C A Heidbreder, D Babovic-Vuksanovic, M Shoaib and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 150-163;

  2. Badger, T

    1. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor.
      K O Lindros, T Badger, M Ronis, M Ingelman-Sundberg and M Koivusalo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 79-83;

  3. Balster, R L

    1. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
      J L Wiley, J A Lowe, R L Balster and B R Martin
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 1-6;

  4. Battistini, B

    1. Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat.
      G H Allcock, B Battistini, A Fournier, T D Warner and J R Vane
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 120-126;

  5. Bauer, R F

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  6. Bellgowan, P S

    1. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats.
      F J Helmstetter, P S Bellgowan and L H Poore
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 381-388;

  7. Bennett, G J

    1. Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy.
      Y Imamura and G J Bennett
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 177-182;

  8. Benvenga, M J

    1. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons.
      M J Benvenga, P L Ornstein and J D Leander
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 164-170;

  9. Böhlen, P

    1. Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats.
      S Kusstatscher, Z Sandor, S Szabo, A Seddon and P Böhlen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 456-461;

  10. Borgeat, P

    1. Leukotriene C4 receptors on guinea pig tracheocytes.
      S Prié, G Guillemette, G Boulay, P Borgeat and P Sirois
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 312-318;

  11. Borsini, F

    1. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study.
      M Volonté, A Ceci and F Borsini
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 358-367;

  12. Boucrot, P

    1. New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation.
      F Lang, J M Robert, P Boucrot, L Welin and J Y Petit
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 171-176;

  13. Boulay, G

    1. Leukotriene C4 receptors on guinea pig tracheocytes.
      S Prié, G Guillemette, G Boulay, P Borgeat and P Sirois
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 312-318;

  14. Bowyer, J F

    1. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response.
      H W Broening, J F Bowyer and W Slikker
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 325-333;

  15. Broening, H W

    1. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response.
      H W Broening, J F Bowyer and W Slikker
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 325-333;

  16. Brooks, D P

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

  17. Burnstock, G

    1. Changes in sympathetic neurotransmission and adrenergic control of cardiac contractility during 1,3-dipropyl-8-sulfophenylxanthine-induced hypertension.
      A Rubino and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 422-428;

  18. Butelman, E R

    1. Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys.
      E R Butelman, C P France and J H Woods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 374-380;

C

  1. Cahill, C M

    1. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
      C M Cahill, T D White and J Sawynok
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 84-93;

  2. Ceci, A

    1. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study.
      M Volonté, A Ceci and F Borsini
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 358-367;

  3. Chen, J

    1. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content.
      J Chen and M M Rasenick
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 509-517;

  4. Cheng, P Y

    1. Opioid modulation of fetal glucose homeostasis: role of receptor subtypes.
      H H Szeto, Y Soong, D L Wu and P Y Cheng
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 334-339;

  5. Chiodo, L A

    1. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole.
      D K Pitts, L Wang, M D Kelland, A S Freeman and L A Chiodo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 412-421;

  6. Chiou, G C

    1. Prevention and reduction of neural damage in ischemic strokes by w-(N,N'-diethylamino)-n-alkyl-3,4,5-trimethoxybenzoate compounds.
      G C Chiou and S J Hong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 474-478;

  7. Christiansen, I

    1. Effects of single and multiple intravenous cocaine injections in humans maintained on methadone.
      R W Foltin, I Christiansen, F R Levin and M W Fischman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 38-47;

  8. Ciabattoni, G

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  9. Collins, P W

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  10. Cooke, M E

    1. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
      R M Crooke, M J Graham, M E Cooke and S T Crooke
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 462-473;

  11. Coy, D H

    1. Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes.
      J T Lin, D H Coy, S A Mantey and R T Jensen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 285-295;

  12. Créminon, C

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  13. Crooke, R M

    1. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
      R M Crooke, M J Graham, M E Cooke and S T Crooke
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 462-473;

  14. Crooke, S T

    1. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
      R M Crooke, M J Graham, M E Cooke and S T Crooke
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 462-473;

  15. Cuadra, G

    1. Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo.
      G Cuadra and E Giacobini
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 228-236;

D

  1. Danhof, M

    1. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
      R A Mathôt, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman and M Danhof
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 245-253;

  2. Dement, W C

    1. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat.
      W F Seidel, M Maze, W C Dement and D M Edgar
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 263-273;

  3. de Waele, J P

    1. Distribution of the mu and delta opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats.
      J P de Waele, K Kiianmaa and C Gianoulakis
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 518-527;

  4. Dirig, D M

    1. Intrathecal baclofen and muscimol, but not midazolam, are antinociceptive using the rat-formalin model.
      D M Dirig and T L Yaksh
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 219-227;

  5. Doods, H N

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

E

  1. Eberlein, W

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

  2. Edgar, D M

    1. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat.
      W F Seidel, M Maze, W C Dement and D M Edgar
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 263-273;

  3. Elliott, J D

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

  4. Engel, W

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

  5. Entzeroth, M

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

F

  1. Fekete, Z

    1. The endothelin receptor profile in L6 myotubes.
      Z Fekete, X Y Yang, M Kimura and A Aviv
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 215-218;

  2. Fernández, E

    1. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats.
      E Fernández, A I Galán, D Morán, J M González-Buitrago, M E Muñoz and R Jiménez
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 442-449;

  3. Fischman, M W

    1. Effects of single and multiple intravenous cocaine injections in humans maintained on methadone.
      R W Foltin, I Christiansen, F R Levin and M W Fischman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 38-47;

  4. Fitzgerald, G A

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  5. Fletcher, T

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

  6. Foltin, R W

    1. Effects of single and multiple intravenous cocaine injections in humans maintained on methadone.
      R W Foltin, I Christiansen, F R Levin and M W Fischman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 38-47;

  7. Fournier, A

    1. Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat.
      G H Allcock, B Battistini, A Fournier, T D Warner and J R Vane
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 120-126;

  8. France, C P

    1. Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys.
      E R Butelman, C P France and J H Woods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 374-380;

  9. Francis, R

    1. Cocaine sensitization in periadolescent and adult rats.
      G Laviola, R D Wood, C Kuhn, R Francis and L P Spear
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 345-357;

  10. Freeman, A S

    1. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole.
      D K Pitts, L Wang, M D Kelland, A S Freeman and L A Chiodo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 412-421;

  11. Fujita, A

    1. Necessity of newly synthesized ATP by creatine kinase for contraction of permeabilized longitudinal muscle preparations of rat proximal colon.
      T Takeuchi, A Fujita, T Ishii, H Nishio and F Hata
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 429-434;

G

  1. Gaginella, T S

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  2. Galán, A I

    1. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats.
      E Fernández, A I Galán, D Morán, J M González-Buitrago, M E Muñoz and R Jiménez
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 442-449;

  3. Gasiecki, A W

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  4. Gekle, M

    1. Time- and concentration-dependent biphasic effect of ochratoxin A on growth of proximal tubular cells in primary culture.
      M Gekle, C A Pollock and S Silbernagl
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 397-404;

  5. Gellai, M

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

  6. Giacobini, E

    1. Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo.
      G Cuadra and E Giacobini
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 228-236;

  7. Gianoulakis, C

    1. Distribution of the mu and delta opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats.
      J P de Waele, K Kiianmaa and C Gianoulakis
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 518-527;

  8. González-Buitrago, J M

    1. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats.
      E Fernández, A I Galán, D Morán, J M González-Buitrago, M E Muñoz and R Jiménez
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 442-449;

  9. Goodman, M

    1. Characterization of the spinal antinociceptive activity of constrained peptidomimetic opioids.
      T L Yaksh, A B Malmberg, S Ro, P Schiller and M Goodman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 63-72;

  10. Graham, M J

    1. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
      R M Crooke, M J Graham, M E Cooke and S T Crooke
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 462-473;

  11. Green, P G

    1. 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.
      P A Pierce, G X Xie, S J Peroutka, P G Green and J D Levine
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 502-508;

  12. Guanowsky, V

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  13. Gubbens-Stibbe, J M

    1. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
      R A Mathôt, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman and M Danhof
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 245-253;

  14. Guillemette, G

    1. Leukotriene C4 receptors on guinea pig tracheocytes.
      S Prié, G Guillemette, G Boulay, P Borgeat and P Sirois
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 312-318;

H

  1. Haeggström, J Z

    1. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
      A Wetterholm, J Z Haeggström, B Samuelsson, W Yuan, B Munoz and C H Wong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 31-37;

  2. Hammond, D L

    1. Microinjection of baclofen in the ventromedial medulla of rats: antinociception at low doses and hyperalgesia at high doses.
      D A Thomas, M K McGowan and D L Hammond
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 274-284;

  3. Harkin, C P

    1. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
      P S Pagel, C P Harkin, D A Hettrick and D C Warltier
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 127-135;

  4. Hartsell, T L

    1. Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
      T L Hartsell, J C Yalowich, M K Ritke, A J Martinez and N F Schor
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 479-485;

  5. Hashizume, K

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  6. Hata, F

    1. Necessity of newly synthesized ATP by creatine kinase for contraction of permeabilized longitudinal muscle preparations of rat proximal colon.
      T Takeuchi, A Fujita, T Ishii, H Nishio and F Hata
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 429-434;

  7. Hayashi, T

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  8. Heidbreder, C A

    1. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
      C A Heidbreder, D Babovic-Vuksanovic, M Shoaib and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 150-163;

  9. Helmstetter, F J

    1. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats.
      F J Helmstetter, P S Bellgowan and L H Poore
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 381-388;

  10. Hettrick, D A

    1. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
      P S Pagel, C P Harkin, D A Hettrick and D C Warltier
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 127-135;

  11. Hidaka, H

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  12. Hirai, M

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  13. Hong, K W

    1. Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat.
      C D Kim and K W Hong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 340-344;

  14. Hong, S J

    1. Prevention and reduction of neural damage in ischemic strokes by w-(N,N'-diethylamino)-n-alkyl-3,4,5-trimethoxybenzoate compounds.
      G C Chiou and S J Hong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 474-478;

  15. Hori, R

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  16. Hossain, M A

    1. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
      M A Hossain and N Weiner
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 237-244;

  17. Howard, H R

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

I

  1. Ijzerman, A P

    1. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
      R A Mathôt, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman and M Danhof
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 245-253;

  2. Imamura, Y

    1. Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy.
      Y Imamura and G J Bennett
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 177-182;

  3. Ingelman-Sundberg, M

    1. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor.
      K O Lindros, T Badger, M Ronis, M Ingelman-Sundberg and M Koivusalo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 79-83;

  4. Ishihara, F

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  5. Ishii, T

    1. Necessity of newly synthesized ATP by creatine kinase for contraction of permeabilized longitudinal muscle preparations of rat proximal colon.
      T Takeuchi, A Fujita, T Ishii, H Nishio and F Hata
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 429-434;

  6. Itoh, N

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

J

  1. Jacobson, K A

    1. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
      R A Mathôt, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman and M Danhof
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 245-253;

  2. Jenck, F

    1. Comparison of benzodiazepine receptor ligands with partial agonistic, antagonistic or partial inverse agonistic properties in precipitating withdrawal in squirrel monkeys.
      J R Martin, F Jenck and J L Moreau
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 405-411;

  3. Jensen, R T

    1. Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes.
      J T Lin, D H Coy, S A Mantey and R T Jensen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 285-295;

  4. Jiménez, R

    1. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats.
      E Fernández, A I Galán, D Morán, J M González-Buitrago, M E Muñoz and R Jiménez
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 442-449;

  5. Johnson, K M

    1. Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. II. The role of calcium, reverse norepinephrine transport and cyclic 3',5'-guanosine monophosphate.
      G Lonart and K M Johnson
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 14-22;
    2. Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. I. The role of glutamate.
      G Lonart and K M Johnson
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 7-13;

  6. Jones, P H

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  7. Jugus, M

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

K

  1. Kaasjager, K A

    1. Interactions of nifedipine with the renovascular effects of endothelin in humans.
      K A Kaasjager, H J van Rijn, H A Koomans and T J Rabelink
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 306-311;

  2. Kagaya, A

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  3. Kakehi, Y

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  4. Kanatani, H

    1. TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats.
      T Ohta, Y Azuma, H Kanatani, M Kiyoki and Y Koshihara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 450-455;

  5. Keith, R H

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  6. Kelland, M D

    1. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole.
      D K Pitts, L Wang, M D Kelland, A S Freeman and L A Chiodo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 412-421;

  7. Kiianmaa, K

    1. Distribution of the mu and delta opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats.
      J P de Waele, K Kiianmaa and C Gianoulakis
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 518-527;

  8. Kim, C D

    1. Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat.
      C D Kim and K W Hong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 340-344;

  9. Kimura, M

    1. The endothelin receptor profile in L6 myotubes.
      Z Fekete, X Y Yang, M Kimura and A Aviv
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 215-218;

  10. King, P D

    1. Hepatic transport of rose bengal by perfused rabbit liver: the effect of albumin binding on the unidirectional rate constants.
      B A Luxon and P D King
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 296-305;

  11. Kinoshita, M

    1. Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium.
      M Kinoshita, E Kume and H Tamaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 494-501;

  12. Kiyoki, M

    1. TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats.
      T Ohta, Y Azuma, H Kanatani, M Kiyoki and Y Koshihara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 450-455;

  13. Kobuchi, H

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  14. Koivusalo, M

    1. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor.
      K O Lindros, T Badger, M Ronis, M Ingelman-Sundberg and M Koivusalo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 79-83;

  15. Kojima, S

    1. Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts.
      S Kojima, S T Wu, J Wikman-Coffelt and W W Parmley
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 254-262;

  16. Komano, T

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  17. Koomans, H A

    1. Interactions of nifedipine with the renovascular effects of endothelin in humans.
      K A Kaasjager, H J van Rijn, H A Koomans and T J Rabelink
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 306-311;

  18. Koshihara, Y

    1. TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats.
      T Ohta, Y Azuma, H Kanatani, M Kiyoki and Y Koshihara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 450-455;

  19. Kruszyna, H

    1. Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin.
      L G Rochelle, S J Morana, H Kruszyna, M A Russell, D E Wilcox and R P Smith
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 48-52;

  20. Kuhn, C

    1. Cocaine sensitization in periadolescent and adult rats.
      G Laviola, R D Wood, C Kuhn, R Francis and L P Spear
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 345-357;

  21. Kume, E

    1. Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium.
      M Kinoshita, E Kume and H Tamaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 494-501;

  22. Kusstatscher, S

    1. Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats.
      S Kusstatscher, Z Sandor, S Szabo, A Seddon and P Böhlen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 456-461;

L

  1. Lang, F

    1. New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation.
      F Lang, J M Robert, P Boucrot, L Welin and J Y Petit
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 171-176;

  2. Laviola, G

    1. Cocaine sensitization in periadolescent and adult rats.
      G Laviola, R D Wood, C Kuhn, R Francis and L P Spear
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 345-357;

  3. Lawson, J

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  4. Leander, J D

    1. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons.
      M J Benvenga, P L Ornstein and J D Leander
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 164-170;

  5. Lebel, L A

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  6. Lee, V H

    1. Role of Na+ in the asymmetric paracellular transport of 4-phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly-L-Pro-D-Arg across rabbit colonic segments and Caco-2 cell monolayers.
      W C Yen and V H Lee
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 114-119;

  7. Levin, F R

    1. Effects of single and multiple intravenous cocaine injections in humans maintained on methadone.
      R W Foltin, I Christiansen, F R Levin and M W Fischman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 38-47;

  8. Levine, J D

    1. 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.
      P A Pierce, G X Xie, S J Peroutka, P G Green and J D Levine
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 502-508;

  9. Lin, J T

    1. Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes.
      J T Lin, D H Coy, S A Mantey and R T Jensen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 285-295;

  10. Lindros, K O

    1. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor.
      K O Lindros, T Badger, M Ronis, M Ingelman-Sundberg and M Koivusalo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 79-83;

  11. Lonart, G

    1. Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. II. The role of calcium, reverse norepinephrine transport and cyclic 3',5'-guanosine monophosphate.
      G Lonart and K M Johnson
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 14-22;
    2. Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. I. The role of glutamate.
      G Lonart and K M Johnson
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 7-13;

  12. Lowe, J A

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;
    2. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
      J L Wiley, J A Lowe, R L Balster and B R Martin
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 1-6;

  13. Luxon, B A

    1. Hepatic transport of rose bengal by perfused rabbit liver: the effect of albumin binding on the unidirectional rate constants.
      B A Luxon and P D King
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 296-305;

M

  1. Maclouf, J

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  2. Malmberg, A B

    1. Characterization of the spinal antinociceptive activity of constrained peptidomimetic opioids.
      T L Yaksh, A B Malmberg, S Ro, P Schiller and M Goodman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 63-72;

  3. Mameya, S

    1. Arachidonic acid cascade and stimulation of acetylcholine release by human recombinant interleukin-1 beta in guinea pig ileum.
      S Mameya, T Sawa and K Taniyama
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 319-324;

  4. Mantey, S A

    1. Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes.
      J T Lin, D H Coy, S A Mantey and R T Jensen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 285-295;

  5. Martin, B R

    1. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
      J L Wiley, J A Lowe, R L Balster and B R Martin
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 1-6;

  6. Martin, J R

    1. Comparison of benzodiazepine receptor ligands with partial agonistic, antagonistic or partial inverse agonistic properties in precipitating withdrawal in squirrel monkeys.
      J R Martin, F Jenck and J L Moreau
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 405-411;

  7. Martinez, A J

    1. Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
      T L Hartsell, J C Yalowich, M K Ritke, A J Martinez and N F Schor
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 479-485;

  8. Martínez, V

    1. Peripheral and central cholecystokinin receptors regulate postprandial intestinal motility in the rat.
      A Rodríguez-Membrilla, V Martínez and P Vergara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 486-493;

  9. Mathôt, R A

    1. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
      R A Mathôt, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman and M Danhof
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 245-253;

  10. Maze, M

    1. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat.
      W F Seidel, M Maze, W C Dement and D M Edgar
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 263-273;

  11. McGowan, M K

    1. Microinjection of baclofen in the ventromedial medulla of rats: antinociception at low doses and hyperalgesia at high doses.
      D A Thomas, M K McGowan and D L Hammond
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 274-284;

  12. McLarnon, J G

    1. Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes.
      J G McLarnon and R Xu
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 389-396;

  13. McLean, S

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  14. Morán, D

    1. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats.
      E Fernández, A I Galán, D Morán, J M González-Buitrago, M E Muñoz and R Jiménez
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 442-449;

  15. Morana, S J

    1. Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin.
      L G Rochelle, S J Morana, H Kruszyna, M A Russell, D E Wilcox and R P Smith
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 48-52;

  16. Moreau, J L

    1. Comparison of benzodiazepine receptor ligands with partial agonistic, antagonistic or partial inverse agonistic properties in precipitating withdrawal in squirrel monkeys.
      J R Martin, F Jenck and J L Moreau
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 405-411;

  17. Mørland, J

    1. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling.
      T A Aasmundstad, J Mørland and R E Paulsen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 435-441;

  18. Motohashi, N

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  19. Munoz, B

    1. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
      A Wetterholm, J Z Haeggström, B Samuelsson, W Yuan, B Munoz and C H Wong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 31-37;

  20. Muñoz, M E

    1. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats.
      E Fernández, A I Galán, D Morán, J M González-Buitrago, M E Muñoz and R Jiménez
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 442-449;

N

  1. Nagasawa, T

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  2. Nakabayashi, T

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  3. Nambi, P

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

  4. Nishio, H

    1. Necessity of newly synthesized ATP by creatine kinase for contraction of permeabilized longitudinal muscle preparations of rat proximal colon.
      T Takeuchi, A Fujita, T Ishii, H Nishio and F Hata
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 429-434;

O

  1. Ohkubo, Y

    1. Tiapride attenuates pain transmission through an indirect activation of central serotonergic mechanism.
      N Takeshita, Y Ohkubo and I Yamaguchi
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 23-30;

  2. Ohlstein, E H

    1. Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.
      M Gellai, M Jugus, T Fletcher, P Nambi, E H Ohlstein, J D Elliott and D P Brooks
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 200-206;

  3. Ohta, T

    1. TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats.
      T Ohta, Y Azuma, H Kanatani, M Kiyoki and Y Koshihara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 450-455;

  4. Ornstein, P L

    1. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons.
      M J Benvenga, P L Ornstein and J D Leander
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 164-170;

P

  1. Pagel, P S

    1. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
      P S Pagel, C P Harkin, D A Hettrick and D C Warltier
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 127-135;

  2. Parmley, W W

    1. Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts.
      S Kojima, S T Wu, J Wikman-Coffelt and W W Parmley
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 254-262;

  3. Patrono, C

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  4. Paulsen, R E

    1. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling.
      T A Aasmundstad, J Mørland and R E Paulsen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 435-441;

  5. Perkins, W E

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  6. Peroutka, S J

    1. 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.
      P A Pierce, G X Xie, S J Peroutka, P G Green and J D Levine
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 502-508;

  7. Petit, J Y

    1. New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation.
      F Lang, J M Robert, P Boucrot, L Welin and J Y Petit
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 171-176;

  8. Pierce, P A

    1. 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.
      P A Pierce, G X Xie, S J Peroutka, P G Green and J D Levine
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 502-508;

  9. Pitts, D K

    1. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole.
      D K Pitts, L Wang, M D Kelland, A S Freeman and L A Chiodo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 412-421;

  10. Pollock, C A

    1. Time- and concentration-dependent biphasic effect of ochratoxin A on growth of proximal tubular cells in primary culture.
      M Gekle, C A Pollock and S Silbernagl
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 397-404;

  11. Poore, L H

    1. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats.
      F J Helmstetter, P S Bellgowan and L H Poore
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 381-388;

  12. Prié, S

    1. Leukotriene C4 receptors on guinea pig tracheocytes.
      S Prié, G Guillemette, G Boulay, P Borgeat and P Sirois
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 312-318;

R

  1. Rabelink, T J

    1. Interactions of nifedipine with the renovascular effects of endothelin in humans.
      K A Kaasjager, H J van Rijn, H A Koomans and T J Rabelink
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 306-311;

  2. Rasenick, M M

    1. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content.
      J Chen and M M Rasenick
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 509-517;

  3. Ritke, M K

    1. Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
      T L Hartsell, J C Yalowich, M K Ritke, A J Martinez and N F Schor
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 479-485;

  4. Ro, S

    1. Characterization of the spinal antinociceptive activity of constrained peptidomimetic opioids.
      T L Yaksh, A B Malmberg, S Ro, P Schiller and M Goodman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 63-72;

  5. Robert, J M

    1. New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation.
      F Lang, J M Robert, P Boucrot, L Welin and J Y Petit
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 171-176;

  6. Rochelle, L G

    1. Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin.
      L G Rochelle, S J Morana, H Kruszyna, M A Russell, D E Wilcox and R P Smith
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 48-52;

  7. Rodríguez-Membrilla, A

    1. Peripheral and central cholecystokinin receptors regulate postprandial intestinal motility in the rat.
      A Rodríguez-Membrilla, V Martínez and P Vergara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 486-493;

  8. Ronis, M

    1. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor.
      K O Lindros, T Badger, M Ronis, M Ingelman-Sundberg and M Koivusalo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 79-83;

  9. Rubino, A

    1. Changes in sympathetic neurotransmission and adrenergic control of cardiac contractility during 1,3-dipropyl-8-sulfophenylxanthine-induced hypertension.
      A Rubino and G Burnstock
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 422-428;

  10. Rudolf, K

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

  11. Russell, M A

    1. Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin.
      L G Rochelle, S J Morana, H Kruszyna, M A Russell, D E Wilcox and R P Smith
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 48-52;

S

  1. Samuelsson, B

    1. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
      A Wetterholm, J Z Haeggström, B Samuelsson, W Yuan, B Munoz and C H Wong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 31-37;

  2. Sandor, Z

    1. Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats.
      S Kusstatscher, Z Sandor, S Szabo, A Seddon and P Böhlen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 456-461;

  3. Sannerud, C A

    1. Drug discrimination analysis of midazolam under a three-lever procedure. II: Differential effects of benzodiazepine receptor agonists.
      C A Sannerud and N A Ator
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 183-193;

  4. Sato, Y

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  5. Sawa, T

    1. Arachidonic acid cascade and stimulation of acetylcholine release by human recombinant interleukin-1 beta in guinea pig ileum.
      S Mameya, T Sawa and K Taniyama
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 319-324;

  6. Sawynok, J

    1. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
      C M Cahill, T D White and J Sawynok
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 84-93;

  7. Schiller, P

    1. Characterization of the spinal antinociceptive activity of constrained peptidomimetic opioids.
      T L Yaksh, A B Malmberg, S Ro, P Schiller and M Goodman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 63-72;

  8. Schmidt, A W

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  9. Schor, N F

    1. Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
      T L Hartsell, J C Yalowich, M K Ritke, A J Martinez and N F Schor
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 479-485;

  10. Schulz, D W

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  11. Seddon, A

    1. Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats.
      S Kusstatscher, Z Sandor, S Szabo, A Seddon and P Böhlen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 456-461;

  12. Seeger, T F

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  13. Seidel, W F

    1. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat.
      W F Seidel, M Maze, W C Dement and D M Edgar
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 263-273;

  14. Seymour, P A

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;

  15. Shimizu, M

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  16. Shimizu, T

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  17. Shippenberg, T S

    1. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
      C A Heidbreder, D Babovic-Vuksanovic, M Shoaib and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 150-163;

  18. Shoaib, M

    1. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
      C A Heidbreder, D Babovic-Vuksanovic, M Shoaib and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 150-163;

  19. Silbernagl, S

    1. Time- and concentration-dependent biphasic effect of ochratoxin A on growth of proximal tubular cells in primary culture.
      M Gekle, C A Pollock and S Silbernagl
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 397-404;

  20. Sirois, P

    1. Leukotriene C4 receptors on guinea pig tracheocytes.
      S Prié, G Guillemette, G Boulay, P Borgeat and P Sirois
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 312-318;

  21. Slikker, W

    1. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response.
      H W Broening, J F Bowyer and W Slikker
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 325-333;

  22. Smith, R P

    1. Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin.
      L G Rochelle, S J Morana, H Kruszyna, M A Russell, D E Wilcox and R P Smith
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 48-52;

  23. Soong, Y

    1. Opioid modulation of fetal glucose homeostasis: role of receptor subtypes.
      H H Szeto, Y Soong, D L Wu and P Y Cheng
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 334-339;

  24. Soudijn, W

    1. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
      R A Mathôt, J M Gubbens-Stibbe, W Soudijn, K A Jacobson, A P Ijzerman and M Danhof
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 245-253;

  25. Spealman, R D

    1. Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys.
      R D Spealman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 53-62;

  26. Spear, L P

    1. Cocaine sensitization in periadolescent and adult rats.
      G Laviola, R D Wood, C Kuhn, R Francis and L P Spear
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 345-357;

  27. Szabo, S

    1. Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats.
      S Kusstatscher, Z Sandor, S Szabo, A Seddon and P Böhlen
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 456-461;

  28. Szeto, H H

    1. Opioid modulation of fetal glucose homeostasis: role of receptor subtypes.
      H H Szeto, Y Soong, D L Wu and P Y Cheng
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 334-339;

T

  1. Taguchi, N

    1. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
      T Aizawa, N Taguchi, Y Sato, T Nakabayashi, H Kobuchi, H Hidaka, T Nagasawa, F Ishihara, N Itoh and K Hashizume
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 194-199;

  2. Takebayashi, M

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  3. Takeshita, N

    1. Tiapride attenuates pain transmission through an indirect activation of central serotonergic mechanism.
      N Takeshita, Y Ohkubo and I Yamaguchi
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 23-30;

  4. Takeuchi, T

    1. Necessity of newly synthesized ATP by creatine kinase for contraction of permeabilized longitudinal muscle preparations of rat proximal colon.
      T Takeuchi, A Fujita, T Ishii, H Nishio and F Hata
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 429-434;

  5. Tamaki, H

    1. Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium.
      M Kinoshita, E Kume and H Tamaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 494-501;

  6. Tanaka, K

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  7. Tanigawara, Y

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  8. Taniyama, K

    1. Arachidonic acid cascade and stimulation of acetylcholine release by human recombinant interleukin-1 beta in guinea pig ileum.
      S Mameya, T Sawa and K Taniyama
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 319-324;

  9. Thomas, D A

    1. Microinjection of baclofen in the ventromedial medulla of rats: antinociception at low doses and hyperalgesia at high doses.
      D A Thomas, M K McGowan and D L Hammond
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 274-284;

  10. Tsai, B S

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

U

  1. Uchitomi, Y

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  2. Ueda, K

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

V

  1. Vane, J R

    1. Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat.
      G H Allcock, B Battistini, A Fournier, T D Warner and J R Vane
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 120-126;

  2. van Rijn, H J

    1. Interactions of nifedipine with the renovascular effects of endothelin in humans.
      K A Kaasjager, H J van Rijn, H A Koomans and T J Rabelink
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 306-311;

  3. Vergara, P

    1. Peripheral and central cholecystokinin receptors regulate postprandial intestinal motility in the rat.
      A Rodríguez-Membrilla, V Martínez and P Vergara
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 486-493;

  4. Volonté, M

    1. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study.
      M Volonté, A Ceci and F Borsini
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 358-367;

W

  1. Walsh, R E

    1. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors.
      B S Tsai, R H Keith, W E Perkins, R E Walsh, C P Anglin, P W Collins, A W Gasiecki, R F Bauer, P H Jones and T S Gaginella
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 368-373;

  2. Wang, L

    1. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole.
      D K Pitts, L Wang, M D Kelland, A S Freeman and L A Chiodo
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 412-421;

  3. Wang, Z

    1. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
      Z Wang, G Ciabattoni, C Créminon, J Lawson, G A Fitzgerald, C Patrono and J Maclouf
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 94-100;

  4. Warltier, D C

    1. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
      P S Pagel, C P Harkin, D A Hettrick and D C Warltier
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 127-135;

  5. Warner, T D

    1. Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat.
      G H Allcock, B Battistini, A Fournier, T D Warner and J R Vane
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 120-126;

  6. Weiner, N

    1. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
      M A Hossain and N Weiner
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 237-244;

  7. Welin, L

    1. New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation.
      F Lang, J M Robert, P Boucrot, L Welin and J Y Petit
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 171-176;

  8. Wetterholm, A

    1. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
      A Wetterholm, J Z Haeggström, B Samuelsson, W Yuan, B Munoz and C H Wong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 31-37;

  9. White, T D

    1. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
      C M Cahill, T D White and J Sawynok
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 84-93;

  10. Wieland, H A

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

  11. Wienen, W

    1. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
      H N Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and H A Wieland
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 136-142;
    2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

  12. Wikman-Coffelt, J

    1. Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts.
      S Kojima, S T Wu, J Wikman-Coffelt and W W Parmley
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 254-262;

  13. Wilcox, D E

    1. Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin.
      L G Rochelle, S J Morana, H Kruszyna, M A Russell, D E Wilcox and R P Smith
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 48-52;

  14. Wiley, J L

    1. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
      J L Wiley, J A Lowe, R L Balster and B R Martin
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 1-6;

  15. Willim, K D

    1. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
      H A Wieland, K D Willim, M Entzeroth, W Wienen, K Rudolf, W Eberlein, W Engel and H N Doods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 143-149;

  16. Wong, C H

    1. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
      A Wetterholm, J Z Haeggström, B Samuelsson, W Yuan, B Munoz and C H Wong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 31-37;

  17. Wood, R D

    1. Cocaine sensitization in periadolescent and adult rats.
      G Laviola, R D Wood, C Kuhn, R Francis and L P Spear
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 345-357;

  18. Woods, J H

    1. Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys.
      E R Butelman, C P France and J H Woods
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 374-380;

  19. Wu, D L

    1. Opioid modulation of fetal glucose homeostasis: role of receptor subtypes.
      H H Szeto, Y Soong, D L Wu and P Y Cheng
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 334-339;

  20. Wu, S T

    1. Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts.
      S Kojima, S T Wu, J Wikman-Coffelt and W W Parmley
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 254-262;

X

  1. Xie, G X

    1. 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.
      P A Pierce, G X Xie, S J Peroutka, P G Green and J D Levine
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 502-508;

  2. Xu, R

    1. Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes.
      J G McLarnon and R Xu
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 389-396;

Y

  1. Yaksh, T L

    1. Intrathecal baclofen and muscimol, but not midazolam, are antinociceptive using the rat-formalin model.
      D M Dirig and T L Yaksh
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 219-227;
    2. Characterization of the spinal antinociceptive activity of constrained peptidomimetic opioids.
      T L Yaksh, A B Malmberg, S Ro, P Schiller and M Goodman
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 63-72;

  2. Yalowich, J C

    1. Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
      T L Hartsell, J C Yalowich, M K Ritke, A J Martinez and N F Schor
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 479-485;

  3. Yamaguchi, I

    1. Tiapride attenuates pain transmission through an indirect activation of central serotonergic mechanism.
      N Takeshita, Y Ohkubo and I Yamaguchi
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 23-30;

  4. Yamawaki, S

    1. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons.
      T Hayashi, A Kagaya, M Takebayashi, M Shimizu, Y Uchitomi, N Motohashi and S Yamawaki
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 207-214;

  5. Yang, X Y

    1. The endothelin receptor profile in L6 myotubes.
      Z Fekete, X Y Yang, M Kimura and A Aviv
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 215-218;

  6. Yasuhara, M

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  7. Yen, W C

    1. Role of Na+ in the asymmetric paracellular transport of 4-phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly-L-Pro-D-Arg across rabbit colonic segments and Caco-2 cell monolayers.
      W C Yen and V H Lee
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 114-119;

  8. Yoshida, O

    1. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
      M Hirai, K Tanaka, T Shimizu, Y Tanigawara, M Yasuhara, R Hori, Y Kakehi, O Yoshida, K Ueda and T Komano
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 73-78;

  9. Yuan, W

    1. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
      A Wetterholm, J Z Haeggström, B Samuelsson, W Yuan, B Munoz and C H Wong
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 31-37;

Z

  1. Zorn, S H

    1. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
      T F Seeger, P A Seymour, A W Schmidt, S H Zorn, D W Schulz, L A Lebel, S McLean, V Guanowsky, H R Howard and J A Lowe
      Journal of Pharmacology and Experimental Therapeutics October 1995, 275 (1) 101-113;
Back to top

In this issue

Advertisement